Negative results of recent randomized clinical trials testing the hypothesis of target therapy for patients with high ontreatment platelet reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 studies with 28.178 patients were included, with amedian age of 66.8 (64–68) and 22.7% (22.4–27.8), of female gender. After amedian follow-up of 1 year (0.1–1), cardiac adverse events occurred in 8.3% (3–11; all results are reported as median and interquartile range) of patients. Pooling all studies together, on-treatment platelet reactivity significantly increased the risk of adverse events (OR 1.33 [1.09, 1.64], ^2= 0%). However, a sensitivity analysis showed that HOPR did not increase the risk of adverse events for patients with ACS, AMI, or stable angina as well as patients resistant to aspirin, ADP antagonists, or both. For all studies, publication bias was formally evident; after adjusting for this,HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89–1.22, 2 0%). Conclusions. After adjusting for clinical confounders (like risk factors and clinical presentation) and for relevant publication bias,HOPR was not an independent prognostic indicator in unselected patients with both stable and unstable coronary disease for an adverse cardiac event.The clinical importance of HOPR for high-risk populations remains to be assessed.

The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis / Fabrizio, D’Ascenzo; Umberto, Barbero; Marta, Bisi; Claudio, Moretti; Pierluigi, Omedè; Enrico, Cerrato; Giorgio, Quadri; Federico, Conrotto; Giuseppe Biondi, Zoccai; James J., Dinicolantonio; Gasparini, Mauro; Sripal, Bangalore; Fiorenzo, Gaita. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - ELETTRONICO. - 2014:(2014), pp. 1-13. [10.1155/2014/610296]

The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis

GASPARINI, Mauro;
2014

Abstract

Negative results of recent randomized clinical trials testing the hypothesis of target therapy for patients with high ontreatment platelet reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 studies with 28.178 patients were included, with amedian age of 66.8 (64–68) and 22.7% (22.4–27.8), of female gender. After amedian follow-up of 1 year (0.1–1), cardiac adverse events occurred in 8.3% (3–11; all results are reported as median and interquartile range) of patients. Pooling all studies together, on-treatment platelet reactivity significantly increased the risk of adverse events (OR 1.33 [1.09, 1.64], ^2= 0%). However, a sensitivity analysis showed that HOPR did not increase the risk of adverse events for patients with ACS, AMI, or stable angina as well as patients resistant to aspirin, ADP antagonists, or both. For all studies, publication bias was formally evident; after adjusting for this,HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89–1.22, 2 0%). Conclusions. After adjusting for clinical confounders (like risk factors and clinical presentation) and for relevant publication bias,HOPR was not an independent prognostic indicator in unselected patients with both stable and unstable coronary disease for an adverse cardiac event.The clinical importance of HOPR for high-risk populations remains to be assessed.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2604979
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo